+1 513 405 6533
Anna - USA

+39 335 736 3517
Office Italy


+1 513 405 6533
Anna - USA

+1 335 736 3517
Office Italy
Our American staff will constantly take care of you
Go to content
About us
CRPS Treatment – company owned by Venitaly (Holding company)

Our Story
Our story begins as one of hope, help, and care being our mission, collaborating with world renowned doctors from the Northeastern region of Italy to provide Neridronate treatment that is elsewhere unavailable.
In 2005, Dott. Claudio Paccanaro, the founder of MTI and it’s subsidiary, CRPS Treatment, attended a medical event at the behest of California’s Gov. Schwarzenegger, with the agenda to send terminally ill cancer patients to the Veneto region of Italy. With 40 years of experience working with the healthcare industry, Dott. Paccanaro attended with great confidence in hopes of bringing top-notch care with breakthrough medicine of Italy to these overseas patients through medical tourism. Once in Italy, the patients would be treated by the best doctors available, and live out their days in the most dignified and pain-free way. Dott. Paccanaro loved the idea of helping patients receive treatment by our fine doctors, realizing that Italy does not just have the best treatments and doctors available, but that it also offers groundbreaking treatments not yet available elsewhere in the world. In 2014, he founded Medical Tourism Italy (MTI) to offer such renowned treatments here in the Veneto region of Italy for breakthrough medicine in care for orthopedic, cancer, and cardiological ailments. Soon, MTI was met with great success, and by word of mouth, we gained traction amongst treating rare health conditions.
In 2015, the company expanded to include CRPS Treatment. After receiving requests for CRPS treatments available, we found that we were the only country in the world offering Neridronate, as it was developed here in the Veneto region of Italy. Neridronate was created specifically for the treatment of Complex Regional Pain Syndrome by our University of Verona’s very own Dr. Adami, who studied the syndrome as his lifelong passion for over 20 years. In 2012, the international medical journal, Rheumatology, published Dr. Adami’s Neridronate study, and was approved by the Italian Administration of Health (AIFA). It has since been standard protocol in Italy when one is diagnosed with CRPS, seeing a 97% remission success rate amongst a population size of 10,000 individuals.

We met with Dr. Adami in 2015, and soon realized that he was eager to work hand-in-hand with us to bring this incredible treatment to everyone. We were able to find the finest hospitals equipped and open to welcome foreign patients, as well as locate the best hotels and accommodations for our patients’ stay in Italy, and provide the best translators to accompany our patients during their stay in Italy. Our service is refined to take the anxiety associated with the disorder away by being there not just as your case manager, but as your care givers while you are here. We also have the privilege of open availability, getting you into treatment as soon as one to two weeks after our doctors review your paperwork.
We pride ourselves in offering a comprehensive experience. We pride ourselves even more in providing an actual treatment for CRPS, as Neridronate re-calcifies from within the body, making it a permanent treatment, rather than merely bandaging the symptoms of CRPS temporarily. While the rest of the world tries to lessen the symptoms, we take a direct approach to fix the problem. Neridronate is the only permanent treatment available for CRPS in the world, and we make it our mission to provide you with nothing but the best in treatment and care.
Copyright © 2014-2018 CRPS Treatment Italy Brand of Venitaly P.IVA IT03725740249
Registered office: Via Degli Uffici del Vicario, 33 - 00186 ROMA - Italy
Administrative office: Via P. Mascagni, 20 - 36100 VICENZA - Italy
Operating office: Galleria Crispi,  43 - 36100 VICENZA - Italy
Tel USA : +1 347 964 0123 | Tel Italy: +39 06 9934 1213 | FAX: +39 0662202062
Back to content